Healx News
Latest Healx news, funding rounds and robotics & AI coverage. 1 article tracked by The Robotics Media.
About Healx
Healx is a Cambridge, UK-based AI-native rare-disease pharmaceutical company founded in 2014 by Tim Guilliams and David Brown. Its proprietary Intelligent Rare Disease Engine and agentic AI drug discovery platform screen combinations of existing and novel compounds against rare-disease biology, moving assets from prediction to patient across a growing clinical pipeline.
Healx has raised more than $100 million to date and is advancing programmes in neurofibromatosis, sarcoma and other high-unmet-need indications.
Key facts
Products by Healx
- HLX-4310 (Software, 2026) — Investigational oral combination therapy pairing a class I selective HDAC inhibitor (domatinostat) with the mTOR inhibitor sirolimus. HLX-4310 is designed to pr...
- Intelligent Rare Disease Engine (Software, 2024) — Healx's proprietary agentic AI drug discovery platform that combines rare-disease knowledge graphs with generative and predictive models to identify high-probab...
- HLX-1502 (Software, 2025) — Investigational small molecule advancing through a Phase 2 trial for the treatment of Neurofibromatosis Type 1, an inherited rare disease that causes tumor grow...
Latest Healx news